Design, synthesis and pharmacological evaluation of novel 2-aryloxazole-based H3 receptor antagonists as potent, antiseizure agents
Authors:
- 14 May 2026
- journal article
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 6863-6882
Abstract
This study aimed to develop novel non-imidazole histamine H3 receptor (H3R) antagonists as potential antiseizure agents. We designed and synthesized a series of 2-aryloxazole derivatives (4a-4t) by relocating a phenyl group from the piperidine side chain to the oxazole core of a previous the lead compound (5 g), aiming to optimize lipophilicity and receptor binding. Among the synthesized compounds, 4f exhibited the most potent H3R antagonistic activity (IC50 = 0.056 µM), superior to lead compound 5 g and the reference drug Pitolisant (PIT). Compound 4f also demonstrated high selectivity over other histamine receptor subtypes (H1R, H2R, and H4R). In vivo, 4f showed significant and sustained antiseizure efficacy in the maximal electroshock (MES) model in mice (ED50 = 17.36 mg/kg) and potently suppressed seizures in a zebrafish pentylenetetrazol (PTZ) model. Pharmacokinetic studies revealed favorable oral bioavailability (81.12%) and effective brain penetration (90 min brain-to-plasma (B/P) ratio = 4.15) with progressive accumulation. Preliminary safety profiling indicated minimal neurotoxicity at therapeutic doses and a lower hERG channel inhibition risk compared to PIT. These results identify 4f as a potent, selective, and brain-penetrable H3R antagonist with robust antiseizure activity and a favorable preclinical profile, supporting its further development as a novel antiseizure agent.Keywords
Funding Information
- National Natural Science Foundation of China (NO.22367014, NO.22167017)
- National Natural Science Foundation of Jiangxi, China (No. 20242BAB23088)
This publication has 51 references indexed in Scilit:
- A sensitive analytical method for the determination of SG-SP1 in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2021
- Synthesis and evaluation of antimicrobial and anticancer activities of 3‐phenyl‐1‐phenylsulfonyl pyrazoles containing an aminoguanidine moietyArchiv der Pharmazie, 2020
- The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmasEuropean Journal of Pharmacology, 2020
- Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic DrugsJAMA Neurology, 2018
- Role of the Histamine H3 Receptor in the Central Nervous System2016
- Pitolisant: First Global ApprovalDrugs, 2016
- Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult ratsNeuropharmacology, 2016
- Neuroprotective effect of ethyl pyruvate against Zn2+ toxicity via NAD replenishment and direct Zn2+ chelationNeuropharmacology, 2016
- Targeting stem cell niches and trafficking for cardiovascular therapyPharmacology & Therapeutics, 2011
- Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expressionNeuroscience, 2005